Characteristics of lung cancer in women: Importance of hormonal and growth factors

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 280-285

  Rouquette, Isabelle ^a   Lauwers Cances, Valérie ^b   Allera, Camille ^a   Brouchet, Laurent ^c   Milia, Julie ^c   Nicaise, Yvan ^a   Laurent, Julie ^b   Delisle, Marie Bernadette ^a   Favre, Gilles ^d   Didier, Alain ^c   Mazières, Julien ^c,d  

^a CHU RANGUEIL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SERVICE DE PNEUMOLOGIE   (France)

^d CHU PURPAN   (France)

Author keywords

EGFR; Estrogen receptor; K Ras; Lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HORMONE ACTION; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE;

ADULT; AGED; FEMALE; HORMONES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SEX FACTORS;

EID: 84860538664     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.023     Document Type: Article

References (37)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Mazieres J., Rouquette I., Brouchet L. Lung cancer in women and pregnancy: towards a hormonal origin?. Rev Mal Respir 2007, 24(8):983-997.
3. Stabile L.P., Siegfried J.M. Sex and gender differences in lung cancer. J Gend Specif Med 2003, 6(1):37-48.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
5. Cadranel J., Zalcman G., Sequist L. Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. Eur Respir J 2011, 37(1):183-193.
6. Siegfried J.M., Hershberger P.A., Stabile L.P. Estrogen receptor signaling in lung cancer. Semin Oncol 2009, 36(6):524-531.
7. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
8. Marquez-Garban D.C., Chen H.W., Fishbein M.C., Goodglick L., Pietras R.J. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007, 72(2):135-143.
9. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62(7):2141-2150.
10. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65(4):1459-1470.
11. Nose N., Sugio K., Oyama T., Nozoe T., Uramoto H., Iwata T., et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009, 27(3):411-417.
12. Raso M.G., Behrens C., Herynk M.H., Liu S., Prudkin L., Ozburn N.C., et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009, 15(17):5359-5368.
13. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
14. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2(8):694-705.
15. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005, 11(14):5084-5089.
16. Ali G., Donati V., Loggini B., Servadio A., Dell'Omodarme M., Prati M.C., et al. Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008, 39(10):1465-1473.
17. Nose N., Uramoto H., Iwata T., Hanagiri T., Yasumoto K. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2010.
18. Kawai H., Ishii A., Washiya K., Konno T., Kon H., Yamaya C., et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005, 25(6C):4693-4698.
19. Jeon Y.K., Sung S.W., Chung J.H., Park W.S., Seo J.W., Kim C.W., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54(3):387-398.
20. Kreuzer M., Gerken M., Heinrich J., Kreienbrock L., Wichmann H.E. Hormonal factors and risk of lung cancer among women?. Int J Epidemiol 2003, 32(2):263-271.
21. Wu C.T., Chang Y.L., Shih J.Y., Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005, 130(4):979-986.
22. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359(13):1367-1380.
23. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997, 3(4):515-522.
24. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22(6):1103-1109.
25. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353(2):133-144.
26. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10(11):760-774.
27. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
28. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
29. Goss G.D.I.L., Tsao M.S., O'Callaghan C.J., Ding K., Masters G.A., Gandara D.R., et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR. 19. ASCO Annual Meeting 2010 2010.
30. Fasco M.J., Hurteau G.J., Spivack S.D. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol Cell Endocrinol 2002, 188(1-2):125-140.
31. Pietras R.J., Marquez D.C., Chen H.W., Tsai E., Weinberg O., Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70(5-7):372-381.
32. Hershberger P.A., Vasquez A.C., Kanterewicz B., Land S., Siegfried J.M., Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005, 65(4):1598-1605.
33. Schwartz A.G., Prysak G.M., Murphy V., Lonardo F., Pass H., Schwartz J., et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005, 11(20):7280-7287.
34. Ishibashi H., Suzuki T., Suzuki S., Niikawa H., Lu L., Miki Y., et al. Progesterone receptor in non-small cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res 2005, 65(14):6450-6458.
35. Mollerup S., Jorgensen K., Berge G., Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37(2):153-159.
36. Stabile L.P., Siegfried J.M. Estrogen receptor pathways in lung cancer. Curr Oncol Rep 2004, 6(4):259-267.
37. Traynor A.M., Schiller J.H., Stabile L.P., Kolesar J.M., Eickhoff J.C., Dacic S., et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009, 64(1):51-59.